INHIBIKASE THERAPEUTICS INC (IKT) Stock News

USA - NASDAQ:IKT - US45719W2052 - Common Stock

1.64 USD

+0.1 (+6.49%)

Last: 9/19/2025, 5:25:12 PM

1.55 USD

-0.09 (-5.49%)

After Hours: 9/19/2025, 5:25:12 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IKT Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

a month ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

a month ago - By: Benzinga - Mentions: IBIO SNGX LIXT ALTS ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: The Motley Fool

Inhibikase Posts Wider Loss in Q2

a year ago - By: BusinessInsider

News Image

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024

a month ago - By: Benzinga - Mentions: SNGX CASI MTNB ADAP ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

4 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

4 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

5 months ago - By: Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

5 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

6 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

6 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

7 months ago - By: Inhibikase Therapeutics

Inhibikase Announces Expansion of Senior Leadership Team

7 months ago - By: Inhibikase Therapeutics

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

7 months ago - By: Inhibikase Therapeutics

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

10 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

10 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

a year ago - By: InvestorPlace

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024